← Back to headlines
Fractyl Health Targets Late 2026 for REMAIN-1 Trial Readout and De Novo Submission
Fractyl Health announced its timeline for the REMAIN-1 pivotal trial readout, expected in early Q4 2026, with plans for a de novo submission to follow in late Q4 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
